Fingerpaint , the global biopharmaceutical marketing partner for integrated analytics-enabled solutions, announced its acquisition of Engage , an award-winning healthcare marketing firm based in London. Details of the transaction were not released.
Engage will expand Fingerpaint’s European presence and complement its current analytics and data expertise.
“The strengthening of our global infrastructure reflects the diversification of the biopharmaceutical industry we serve around the world,” said Ed Mitzen , founder of Fingerpaint. “Our combined global data-driven omnichannel marketing solutions will advance Fingerpaint’s position as a transformative digital partner to meet the marketing needs of the biopharmaceutical industry.”
Mary McGregor and Dave Chandler , founders and managing partners of Engage, will continue to run day-to-day operations.
Also Read: Leveraging AI-Fuelled Metadata to Enhance Content Marketing Strategy
“The integration with Fingerpaint will allow us to leverage their recognized creative and digital talent and maximize omnichannel campaigns as we continue to work with global brands at every stage of the go-to-market,” said McGregor.
“Combining our expertise with Fingerpaint’s will create best-in-class performance-based digital capabilities for clients of the company’s integrated firms,” said Chandler.
Knox Lane, a San Francisco- based private equity firm , is a strategic investor in Fingerpaint.
“Engage will help expand the data and analytics capabilities the industry has come to expect from Fingerpaint, the leading commercialization partner in the biopharmaceutical industry,” said Knox Lane Partner Shamik Patel .
Engage joins Fingerpaint’s integrated firms: MedThink, a company that empowers healthcare providers through medical communications; Leaderboard Branding, a world leader in branding and branding; 1798, a marketing and market access company that specializes in healthcare consulting services, including patient and provider access services; and Photo 51, a consulting company that focuses solely on advanced therapies, such as gene and cell therapies.
For more such updates follow us on Google News TalkCMO News.
